FDA approves Vabysmo prefilled syringe for retinal diseases

Key takeaways:

• The prefilled syringe is indicated for wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion.
• The syringe will be available in the U.S. later this year.

The FDA approved the Vabysmo 6-mg single-dose prefilled syringe for the treatment of wet age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion, according to a Genentech press release.

Vabysmo (faricimab-svoa, Genentech) was previously approved for wet AMD, DME, and retinal vein occlusion (RVO), according to the release, with the pre-filled syringe (PFS) offering an “alternative, ready-to-use format” for delivering the drug. It is the first and only bispecific antibody approved for the eye and has demonstrated positive results in vision improvement and retinal drying in wet AMD, DME, and RVO, according to the release.

Source: Healio

Link: https://www.healio.com/news/ophthalmology/20240705/fda-approves-vabysmo-prefilled-syringe-for-retinal-diseases?utm_source=selligent&utm_medium=email&utm_campaign=news